Skip to content

Effect of Bushen Antai Decoction on Clinical Pregnancy Rate in Frozen-Thawed Embryo Transfer Cycles for Patients with Polycystic Ovary Syndrome: A Multicenter, Randomized, Controlled Clinical Trial

Effect of Bushen Antai Decoction on Clinical Pregnancy Rate in Frozen-Thawed Embryo Transfer Cycles for Patients with Polycystic Ovary Syndrome: A Multicenter, Randomized, Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122822
Enrollment
Unknown
Registered
2026-04-19
Start date
2026-04-20
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Chinese Medicine Group:Bushen Antai Decoction Granules (Astragalus membranaceus 30g, Angelica sinensis 20g, Ligusticum chuanxiong 10g, Cuscuta chinensis 20g, Taxillus chinensis 15g, Dipsacus asper 15g

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
No minimum to 40 Years

Inclusion criteria

Inclusion criteria: 1. Met the Rotterdam diagnostic criteria for PCOS; 2. Patients who have undergone at least two consecutive transfer cycles (fresh or thawed transfer cycles) and have not achieved clinical pregnancy after transferring two high-quality blastocysts or four high-quality cleavage-stage embryos, and are planning to undergo another thawed transfer (with available high-quality blastocysts in storage); 3. Age < 40 years; 4. Patients agreed to receive the treatment of this group and signed informed consent forms.1) Meeting the Rotterdam PCOS diagnostic criteria;

Exclusion criteria

Exclusion criteria: 1. PGT cycle; recurrent miscarriage; genital tract malformations; intrauterine adhesions; thin endometrium (<7mm); submucosal uterine fibroids or intramural fibroids affecting cavity morphology; moderate-to-severe endometriosis; autoimmune diseases; chromosomal abnormalities in either partner. 2. Hydrosalpinx without prior ligation or salpingectomy. 3. Received TCM therapies (e.g., acupuncture) within the past 3 months. 4. Patients undergoing testicular sperm extraction (TESE) or micro-TESE. 5. Severe primary diseases of the heart, liver, lungs, kidneys, brain, or hematologic system; or psychiatric disorders. 6. Endocrine disorders caused by other primary diseases, such as adrenal hyperplasia, hyperprolactinemia, thyroid diseases, or tumors. 7. Severe adverse reactions to study drugs. 8. Unwillingness to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate;

Secondary

MeasureTime frame
Endometrial Thickness (on the day of endometrial transformation);Embryo implantation rate;Persistent pregnancy rate;Live birth rate;Early miscarriage rate;Late miscarriage rate;Uterine endometrial hemodynamic parameters (RI, PI, S/D);

Countries

China

Contacts

Public ContactXu Bei

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

bei_bei81@126.com+86 136 5986 3501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026